Partner Headlines - FOLD

  1. NPS Pharmaceuticals Spikes 19% Amid Shire Bid Report

    Benzinga
  2. These 4 Biotech Stocks Have Been On Fire

    Benzinga
  3. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Mid-Day Losers From November 18: Omega Protein, Urban Outfitters, ...

    Benzinga
  6. Mid-Afternoon Market Update: Tyson Rises After Q4 Results; DreamWorks ...

    Benzinga
  7. Mid-Day Market Update: Allergan Jumps On Actavis Bid; Denbury ...

    Benzinga
  8. Midday Gainers From November 17: Celldex Therapeutics, Amicus ...

    Benzinga
  9. Mid-Morning Market Update: Markets Edge Lower; Halliburton To ...

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. Benzinga's Top #PreMarket Gainers

    Benzinga
  12. Top 5 Biotech Stocks Over The Past Year

    Benzinga
  13. 3 Cheap Biotech Stocks Analysts Love: Ohr Pharmaceutical Inc, ...

    Benzinga
  14. Top 5 Performing Biotech Stocks Of 2014

    Benzinga
  15. Morning Market Movers

    Benzinga
  16. The Biotech Stock With The Best One-Week Performance

    Benzinga
  17. Stocks Hitting 52-Week Highs

    Benzinga
  18. Morning Market Movers

    Benzinga
  19. Benzinga's Top #PreMarket Gainers

    Benzinga
  20. Morning Market Movers

    Benzinga
  21. Amicus Extending Rally On Upgrades

    Benzinga
  22. Benzinga's Top Upgrades

    Benzinga
  23. Benzinga's Top #PreMarket Gainers

    Benzinga
  24. Morning Market Movers

    Benzinga
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. Earnings Scheduled For March 3, 2014

    Benzinga
  27. UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious ...

    Benzinga
  28. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  29. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  30. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  31. Amicus, Biogen Announce Deal for Discovery, Development, Commercialization ...

    Benzinga
  32. Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry ...

    Benzinga
  33. Amicus Therapeutics Advances Chaperone-ERT Combo Platform in ...

    Benzinga
  34. Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme ...

    Benzinga
  35. Stocks Hitting 52-Week Lows

    Benzinga
  36. UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform ...

    Benzinga
  37. Option Traders Call a Bottom for Amicus Therapeutics

    SchaeffersResearch
  38. GlaxoSmithKline

    IBD
  39. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period ...

    Benzinga
  40. Amicus Therapeutics Announces Additional Preliminary Results ...

    Benzinga
  41. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  42. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  43. UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus ...

    Benzinga
  44. Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume ...

    FoxBusiness
  45. Benzinga's Top Upgrades with Color for May 8, 2012

    Benzinga
  46. UPDATE: J.P. Morgan Upgrades Amicus Therapeutics

    Benzinga
  47. From Earlier: Amicus Therapeutics Prices Underwritten Offering ...

    Benzinga
  48. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-K)

    GuruFocus
  49. Amicus Therapeutics Presents Preclinical Studies of Chaperone ...

    Benzinga
  50. Amicus Therapeutics Announces Positive Preliminary Results From ...

    Benzinga
Trading Center